Advertisement

Calcium entry blockers in the treatment of peripheral obliterative arterial disease

  • T. Di Perri
  • F. Laghi Pasini
  • M. Guerrini
Chapter
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 40)

Summary

Important pharmaco-clinical criteria for selecting calcium entry blockers useful in the treatment of peripheral obliterative arterial disease (POAD) seem to be:
  1. 1.

    potent antivasoconstrictor activity, which does not mean generalized vasodilator activity;

     
  2. 2.

    antagonism of blood hyperviscosity;

     
  3. 3.

    potentiation of vascular defense mechanisms such as reactive hyperemia.

     

The clinical results with selective calcium entry blockers in terms of relief of symptoms and particularly in terms of increase of walking distance are worthwhile.

Keywords

Peak Flow Intermittent Claudication Reactive Hyperemia Calcium Entry Blocker Obstructive Peripheral Arterial Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Résumé

On peut distinguer plusieurs critères pharmaco-cliniques importants dans le choix de bloqueurs de l’entrée de calcium utilisables pour le traitement de troubles de la circulation périphérique:
  1. 1.

    action antivasoconstrictrice puissante, ce qui ne veut pas dire vasodilatation générale;

     
  2. 2.

    antagonisme de l’hyperviscosité sanguine;

     
  3. 3.

    potentialisation de mécanismes de défense vasculaires, tels que l’hyperémie réactionnelle.

     

Les résultats cliniques obtenus avec les inhibiteurs de l’entrée de calcium sont très valables en ce qui concerne la diminution des symptômes, et en particulier en ce qui concerne l’augmentation du périmètre de marche.

Resumen

Los criterios siguientes parecen ser importantes para seleccionar distintos inhibidores de la penetración intracelular de Ca2+ por el tratamiento de trastornos obliterativos de la circulación periférica :
  1. 1.

    una fuerte actividad antivasoconstrictora, pero nó una vasodilatación general excesiva;

     
  2. 2.

    un antagonismo de hyperviscosidad de la sangre;

     
  3. 3.

    una mejoración de mecanismos vasculares defensivas como la hiperemía reactiva.

     

Los resultados clínicos obtenidos con inhibidores selectivos de la penetración intracelular del calcio son positivos en cuanto a la disminución de los síntomas y a la aumentación del trecho de marcha de los pacientes.

Zusammenfassung

Für die Selektion von Kalziumeintritthemmern bei der Behandlung von peripheren obliterativen Durchblutungsstörungen sind die folgenden Eigenschaften offensichtlich anzustreben:
  1. 1.

    Ausgeprägte antivasokonstriktorische Wirkung, was nicht bedeutet, dass eine allgemeine Vasodilatation erwünscht wäre;

     
  2. 2.

    Hemmung der Hyperviskosität des Blutes;

     
  3. 3.

    Verbesserung von vaskulären Adaptationsmechanismen, z.B. der reaktiven Hyperämie.

     

Die klinischen Resultaten mit selektiven Kalziumeinstromhemmern sind beachtlich, sowohl vom Standpunkt der Verbesserung von Symptomen als auch der Verlängerung der Gehstrecke bei den Patienten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Di Perri, T. Rheological factors in circulatory disorders. Angiology, 30, 480–486 (1979).PubMedCrossRefGoogle Scholar
  2. Di Perri, T., Forconi, S., Guerrini, M., Laghi Pasini, F., Del Cipolla, R., Rossi, C. and Agnusdei, D. Action of cinnarizine on the hyperviscosity of blood in patients with peripheral obliterative arterial disease. Angiology, 30, 13 (1979a).PubMedCrossRefGoogle Scholar
  3. Di Perri, T., Forconi, S., Guerrini, M., Pecchi, S., Cappelli, R. and Bruni, F. The post-ischemic hyperemia: a strain gauge plethysmographic study in normal subjects and in vascular disease. In: Haemodynamique des Membres, P. Puel, H. Boccalon, A. Enjalbert Eds., 159, Toulouse-France (1979b).Google Scholar
  4. Di Perri, T., Forconi, S., Guerrini, M., Pecchi, S., Cappelli, R. Modificazioni emoreoliche nelle arteriopatie. Giorn. Gerani., 29, 487 (1981).Google Scholar
  5. Emanuel, M.B. Specific calcium antagonists in the treatment of peripheral vascular disease. Angiology, 30, 454–469 (1979).PubMedCrossRefGoogle Scholar
  6. Forconi, S. Continuous measurement of peripheral blood flow by venous occlusion strain gauge plethysmography. Atherosclerosis Reviews, 10, Hegyeli, R.J., Ed., Raven Press, 143, New York (1983).Google Scholar
  7. Gillespie, J.A. The case against vasodilator drugs in occlusive vascular disease of the legs. Lancet, 3, 995 (1959).CrossRefGoogle Scholar
  8. Hladovec, J. and De Clerck, F. Protection by flunarizine against endothelial cell injury in vivo. Angiology, 32, 448–462 (1981).PubMedCrossRefGoogle Scholar
  9. Jageneau, A. and Haag, F. Flunarizin bei Patienten mit Durchblutungsstörungen den unteren Extremitäten: Doppelblindstudie. Med. Welt, 28, 1050–1055 (1977).PubMedGoogle Scholar
  10. Lorentsen, E. and Landmark, K. The acute effect of nifedipine on calf and forefoot blood flow in patients with peripheral arterial insufficiency. Angiology, 34, 46–52 (1983).PubMedCrossRefGoogle Scholar
  11. Nelson, M., Dewitz, G., Dom, J. and Hörig, Ch. Trial of the activity of Sibelium (flunarizine) in circulatory disorders. A multicentre double blind study. Med. Welt, 29/30, 1175–1181 (1978).Google Scholar
  12. Rudofsky, G., Brock, F.E., Elrich, M. and Nobbe, F. Clinical evaluation of flunarizine: walking distance, ergometric performance and hemodynamic and biochemical effects. Angiology, 30, 470–479 (1979).PubMedCrossRefGoogle Scholar
  13. Schetz, J., Bostoen, H., Clement, D., Fornhoff, M., Haerens, A., Roekaerts, P. and Staessen, A.J. Flunarizine in chronic obstructive peripheral arterial disease: a placebo-controlled, double-blind, randomized multicentre trial. Current Therapeutic Res., 23, 121–130 (1978).Google Scholar
  14. Staessen, A.J. Treatment of circulatory disturbances with flunarizine and cinnarizine. A multicentre, double-blind and placebo-controlled evaluation. Vasa, 6, 59–71 (1977).PubMedGoogle Scholar
  15. Verhaegen, H., Roels, V., Adriaensen, H., Brugmans, J., De Cock, W., Dony, J., Jageneau, A. and Schuermans, V. The arteriolar effects of cinnarizine and flunarizine. Angiology, 25, 261–278 (1974).PubMedCrossRefGoogle Scholar
  16. Verhaegen, H., Reyntjens, A., Hörig, Ch. and Pötsch, W. Responsiveness of various symptoms of vascular disorders to calcium antagonists. Angiology, 30, 447–453 (1979).PubMedCrossRefGoogle Scholar
  17. Wellens, D., Goossens, T. and Reyntjens, A. Positive hemokinetic effects after selective calcum-antagonism. Angiology, 31, 821–827 (1980).PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, The Hague 1984

Authors and Affiliations

  • T. Di Perri
  • F. Laghi Pasini
  • M. Guerrini

There are no affiliations available

Personalised recommendations